Follow CVS Health to never miss an important update.
CVS released an analysis showing that popular weight-loss drugs, known as GLP-1s, actually save money on total healthcare when they cost less than $350 per month. These drugs mimic hormones to reduce appetite and help patients manage weight and diabetes. By comparing patients on these medicines to those without them, the company found that the long-term health benefits can outweigh the high cost of the prescriptions.
This is a useful data point for CVS as it negotiates with drugmakers and employers. As a company that both pays for care through its Aetna insurance arm and manages drug plans through Caremark, CVS needs to find a price point where these expensive treatments don't break the budget. Showing a clear path to savings helps the company justify covering the drugs while pushing manufacturers to lower their prices.
Source: New York Post
Chief Executive David Joyner clarified that the company has not received any offers for its retail pharmacy chain. This comes as the healthcare giant moves forward with a plan to spin off the stores into a separate company by the middle of next year, while keeping its insurance and pharmacy benefit arms together.
A spinoff usually means giving current shareholders stock in a new, independent company rather than selling the business to a buyer for cash. These comments suggest that a clean sale is not currently on the table, and the company is sticking to its plan to let the retail unit stand on its own. For owners, this reinforces that the path to unlocking value will likely come through managing two separate stocks rather than a one-time cash payout from a sale.
Source: Bloomberg Markets and Finance
Prem Shah, who serves as an executive vice president and group president, bought about 2 million dollars of CVS stock on the open market. This is a significant personal investment that happened just days after the company announced its massive plan to split its retail pharmacies away from its insurance business.
When a high-ranking executive puts their own money into the stock, it often shows they have confidence in the company's new direction. This is particularly notable now as CVS works through a complex breakup and tries to fix profit issues in its Medicare insurance plans.
After CVS Health reported its November results, we cut our quality score to 2.6. We moved our rating from Buy to Watch. We have added the potential split of the business and the decline in government quality ratings for Medicare plans to our list of risks. We raised our projections for sales and profit for the year ahead.
CVS has decided to split its business into two separate companies, one focused on insurance and the other on its pharmacy and retail operations. This is a major shift away from the company's long-standing strategy of keeping insurance, clinics, and drugstores under one roof to control more of the healthcare process.
While the integrated model was meant to lower costs, it also made the company complex and difficult to manage. Separating the units could allow each business to focus on its own challenges, but it also means losing the potential cost advantages of owning the entire patient journey. We will need to see the specific terms of the split to understand how it affects the value for current owners.
Source: Barrons
Management consistently sets a low bar and clears it, with eight straight quarters of beating their own profit targets even as they navigate a massive corporate breakup.
| Expectation | |
|---|---|
| EPS | $1.03 |
| Revenue | $107.75B |